Corleen Roche is the Chief Financial Officer at Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company developing novel T cell-based cancer immunotherapies. With more than 25 years of finance and accounting experience in the biopharmaceutical sector, Roche brings a proven track record of leading financial operations through complex milestones, including initial public offerings, mergers and acquisitions, and commercial launches. She began her career in public accounting at KPMG LLP, where she developed deep expertise in SEC reporting, technical accounting, and auditing for life sciences companies. Prior to joining Iovance in 2022, Roche served as CFO at Nektar Therapeutics from 2020 to 2022, overseeing financial strategy during pivotal clinical trials and partnership negotiations. She previously held the CFO role at Relypsa, Inc. from 2016 to 2019, successfully navigating the company's IPO on NASDAQ and its subsequent $1.3 billion acquisition by Vifor Pharma (a Galenica Group company). Earlier positions include Vice President of Finance at Onyx Pharmaceuticals, Senior Director of Finance at Genentech, and various finance leadership roles at Gilead Sciences, where she contributed to blockbuster product launches and global financial planning. In her current role at Iovance, Roche directs all aspects of financial planning, reporting, investor relations, and capital allocation, supporting the company's transition to commercialization with its lead therapy, Amtagvi (lifileucel), the first FDA-approved tumor-infiltrating lymphocyte therapy for advanced melanoma. Her strategic oversight has been key in raising over $400 million in equity financing, optimizing cash runway, and ensuring compliance amid rapid growth and regulatory achievements.